Dancann Pharma investor relations material

The company, through its subsidiary Kron Medical ApS, develops a portfolio of novel cannabinoid therapies on the basis of patented technology platforms in the areas of pain, cancer, and brain diseases/disorders. It is also developing medicines for the treatment of infantile spasms or seizures; and a class of drugs for the treatment of various conditions caused by redox signalling imbalance. The company was founded in 2015 and is based in Odense, Denmark